Comparative Evaluation of Fixed Dose Combinations of Fluticasone/ Formoterol and Budesonide/ Formoterol in Patients of Mild - Moderate Bronchial Asthma
Anaesthesia & Critical Care Medicine Journal · 2016
DOI: 10.23880/accmj-16000110 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anaesthesia & Critical Care Medicine Journal, 2016. Verfasst von Shaveta Kaushal. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
The prevalence of asthma is rising worldwide with 10-12% adults and 15% children affected presently.It can have a considerable impact on the quality of life of both, patients and their caregivers.Fixed dose combination of Inhaled corticosteroids (ICS) like fluticasone and budesonide and long acting beta 2 agonists (LABAs) in the form of metered dose inhaler (MDI) are synergistic in action and provide effective control in asthma.
Objectives
In the present study, two ICS & LABA combinations i.e. fluticasone/ formoterol and budesonide/ formoterol were compared, both administered through a metered dose inhaler (MDI) with a spacer, for achieving and maintaining asthma control, improving symptoms, pulmonary function tests and quality of life in patients of mild to moderate bronchial asthma.
Methods
It was a prospective, open-label, randomized, parallel study conducted for a total duration of 12 weeks.The parameters used to compare the two MDIs at 0, 6 and 12 weeks were: a. Pulmonary function tests -FEV1, PEFR b.Asthma control scoring (according to the GINA definition of "control") c.Standardized Asthma Quality of Life Questionnaire [AQLQ(S)] d.Adverse effect profile Results: By the end of 12 weeks, asthma control was similarly achieved among the two groups except that fluticasone/ formoterol was significantly better than budesonide/ formoterol in reducing the need for rescue bronchodilator use (p= 0.000) and in improving daytime symptoms at 6 weeks (p=0.000).Fluticasone/ formoterol at 6 weeks, significantly increased the percent predicted PEFR (p= 0.007) and percent improvement in AQLQ(S) score (p=0.006) in comparison to budesonide/ formoterol.
Conclusion
Fixed dose combination MDIs containing fluticasone/ formoterol and budesonide/ formoterol are effective in elevating pulmonary functions, controlling & relieving symptoms and revamping the quality of life in patients of bronchial asthma.Fluticasone/ formoterol were better in providing a more rapid and greater improvement in percent predicted PEFR, controlling daytime symptoms for a longer time and reducing the need for rescue therapy.Both the treatments were well tolerated.
Zitieren
APA
Kaushal, S. (2016). Comparative Evaluation of Fixed Dose Combinations of Fluticasone/ Formoterol and Budesonide/ Formoterol in Patients of Mild - Moderate Bronchial Asthma. Anaesthesia & Critical Care Medicine Journal. https://doi.org/10.23880/accmj-16000110
Vancouver
Kaushal S. Comparative Evaluation of Fixed Dose Combinations of Fluticasone/ Formoterol and Budesonide/ Formoterol in Patients of Mild - Moderate Bronchial Asthma. Anaesthesia & Critical Care Medicine Journal. 2016. doi:10.23880/accmj-16000110
BibTeX
@article{Kaushal2016,
author = {Kaushal, Shaveta},
title = {Comparative Evaluation of Fixed Dose Combinations of Fluticasone/ Formoterol and Budesonide/ Formoterol in Patients of Mild - Moderate Bronchial Asthma},
journal = {Anaesthesia & Critical Care Medicine Journal},
year = {2016},
doi = {10.23880/accmj-16000110}
}
EUVIMED